{ "schema_version": "chamgap-public-criteria-1.0", "title": "Aged garlic extract 2.4-7.2 g/day × Reduction of ex vivo platelet aggregation", "language": "en", "translation_date": "2026-10-26", "criteria_version": "1.2", "criteria_date": "2026-10-05", "condition_origin": "Chamgap's own application conditions", "method_sources": [ { "id": "M03", "version": "Cochrane Handbook 6.5 (2024), chapter updated 2023-08", "url": "https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-03", "section": "§3.1, §3.2.1–3.2.3, MECIR C5/C7/C13", "official_principle": "Clearly record the question, eligibility conditions and reasons for changes, and distinguish variations in interventions.", "review_level": "Retained method-application records were reused. External originals were not reread and method content was not reassessed." }, { "id": "M04", "version": "Cochrane Handbook 6.5.1 (2025), chapter updated 2025-03", "url": "https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-04", "section": "§4.5, §4.6.1–4.6.3, MECIR C42", "official_principle": "Distinguish studies from reports and link them; do not omit a study solely because results are unreported.", "review_level": "Retained method-application records were reused. External originals were not reread and method content was not reassessed." }, { "id": "M08", "version": "Cochrane Handbook 6.5 (2024), chapter updated 2019-10", "url": "https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-08", "section": "§8.1–8.2.3, Table 8.2.a", "official_principle": "Define the outcome and effect of interest, then examine randomization, deviations, missing data, measurement and selective reporting.", "review_level": "Retained method-application records were reused. External originals were not reread and method content was not reassessed." }, { "id": "M15", "version": "Cochrane Handbook 6.5 (2024), chapter updated 2023-08", "url": "https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-15", "section": "§15.2.4, §15.3.1–15.3.3", "official_principle": "Distinguish effect estimates, intervals, importance and applicability. Sample size alone does not determine precision.", "review_level": "Retained method-application records were reused. External originals were not reread and method content was not reassessed." }, { "id": "M19", "version": "Cochrane Handbook 6.5 (2024), chapter updated 2019-10", "url": "https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-19", "section": "§19.1.2, §19.2.1–19.2.4", "official_principle": "Harm questions may require different designs, populations and follow-up from efficacy questions. Case reports do not establish incidence rates.", "review_level": "Retained method-application records were reused. External originals were not reread and method content was not reassessed." } ], "status_dictionary": { "Met": "Limited verification of the retained identity, observation or scope required by this row. This is separate from clinical sufficiency or full-text certification.", "Partly verified": "Some facts needed by the question are known, while the stated analysis, population, formulation or denominator remains unverified.", "Unverified": "Direct information for this question is unverified in the retained scope. This does not mean an effect of 0, no studies, no harm or an unreviewed table.", "Not applicable": "A specific extension obligation lies outside the narrow question. This does not substitute for unread or unverified material.", "Not applicable (alias)": "A grey-display alias of Not applicable.", "Not read": "The external material was not directly read in the current work. This is separate from reading the retained local summary.", "Conflicting data": "Actual disagreement between reports under the same conditions. Differences between other questions alone do not establish conflict." }, "requirements": [ { "item_id": "N01", "question_type": "Evidence condition", "question": "Is the broad parent text distinguished from the arachidonic acid result-gap question?", "needed": "The original broad claim, endpoint name in the crux, derived comparison and change history.", "role": "Required", "role_reason": "Distinguish a named endpoint's evidence gap from the existing broad parent verdict.", "application_exception": "This subquestion is not an original subclaim and creates no separate clinical grade.", "criterion": "Keep the original effect statement and empty subclaim list unchanged; separately fix the question of direct AGE evidence for arachidonic acid-induced responses.", "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.", "condition_origin": "These are in-house application conditions for the gap in direct AGE results for arachidonic acid-induced aggregation, developed with knowledge of the retained content. They do not establish blinding, clinical preregistration, official-method certification or independent clinical validation.", "proposed_research": "If the question changes, compare the explicitly named original endpoint with the new scope." }, { "item_id": "N02", "question_type": "Evidence condition", "question": "Is a direct AGE arachidonic acid report and comparison verified?", "needed": "Original reports, methods, results and citations linking AGE, arachidonic acid and an actual comparator.", "role": "Required", "role_reason": "Do not fill an empty result with an invented report.", "application_exception": "Do not turn a gap in the current summary into worldwide absence of studies, existence of a paper or a null effect.", "criterion": "Identify an actual report establishing formulation, population, arachidonic acid endpoint, placebo and timing together.", "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.", "condition_origin": "These are in-house application conditions for the gap in direct AGE results for arachidonic acid-induced aggregation, developed with knowledge of the retained content. They do not establish blinding, clinical preregistration, official-method certification or independent clinical validation.", "proposed_research": "First compare this endpoint against the complete plans/results of the current 3 reports; record the presence or absence of direct material within a stated scope." }, { "item_id": "N03", "question_type": "Evidence condition", "question": "Are the selected AGE identity and actual arachidonic acid trial-product specifications verified?", "needed": "Product name, manufacture/aging, batch, SAC/ingredients and comparison specifications in methods for the selected response.", "role": "Required", "role_reason": "Do not transfer selected-response results to another garlic formulation or isolated ingredient.", "application_exception": "Do not assume that the 1995 garlic preparation is AGE or an arachidonic acid trial product.", "criterion": "Distinguish the broad AGE capsule identity from the product/batch, SAC, manufacture/aging and ingredients used for the selected response.", "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.", "condition_origin": "These are in-house application conditions for the gap in direct AGE results for arachidonic acid-induced aggregation, developed with knowledge of the retained content. They do not establish blinding, clinical preregistration, official-method certification or independent clinical validation.", "proposed_research": "Verify the product's molecular identity, manufacture and specifications before comparing result eligibility." }, { "item_id": "N04", "question_type": "Evidence condition", "question": "Are actual route, dose and intake linked to the arachidonic acid result verified?", "needed": "Product/administration records, intake/adherence, changes/discontinuation and a measurement linkage table for the selected response.", "role": "Required", "role_reason": "The stated amount for another result does not establish exposure for the selected response.", "application_exception": "Do not substitute the nominal 7.2 g/day in the parent dose list or the weak ADP threshold signal at the highest dose for actual arachidonic acid dose/effect. The link between nominal doses and the ADP result cell also remains unverified.", "criterion": "Directly verify the route, product/active amount, frequency and adherence of exposure in which this response was measured.", "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.", "condition_origin": "These are in-house application conditions for the gap in direct AGE results for arachidonic acid-induced aggregation, developed with knowledge of the retained content. They do not establish blinding, clinical preregistration, official-method certification or independent clinical validation.", "proposed_research": "Link exposure records to aggregation-test participants; separate broad nominal doses from actual amounts for the selected response." }, { "item_id": "N05", "question_type": "Evidence condition", "question": "Are the actual population, eligibility and baseline status for the arachidonic acid response verified?", "needed": "Population/eligibility, baseline tables, medication/disease exclusions and analysis population for the selected response.", "role": "Required", "role_reason": "Do not repurpose a population from another result as the direct selected-response population.", "application_exception": "Do not treat healthy adults, 34 people or a small male sample as an established selected-response population.", "criterion": "Verify population, inclusion/exclusion, baseline function, disease/co-medication and actual analysis population in the selected-response report.", "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.", "condition_origin": "These are in-house application conditions for the gap in direct AGE results for arachidonic acid-induced aggregation, developed with knowledge of the retained content. They do not establish blinding, clinical preregistration, official-method certification or independent clinical validation.", "proposed_research": "Link actual participants to aggregation-test data; do not expand applicability using a broad population label." }, { "item_id": "N06", "question_type": "Evidence condition", "question": "Are arachidonic acid exposure duration and testing times verified?", "needed": "Administration/discontinuation, washout, blood-draw/testing schedules and result times for the selected response.", "role": "Required", "role_reason": "Do not convert nominal short-term wording into a specific selected-response assessment time.", "application_exception": "Do not automatically inherit another trial's duration or persistence of effect.", "criterion": "Link administration, discontinuation/washout, blood draw and testing times under the same comparison conditions.", "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.", "condition_origin": "These are in-house application conditions for the gap in direct AGE results for arachidonic acid-induced aggregation, developed with knowledge of the retained content. They do not establish blinding, clinical preregistration, official-method certification or independent clinical validation.", "proposed_research": "Compare planned and actual testing dates; distinguish responses at different times." }, { "item_id": "N07", "question_type": "Evidence condition", "question": "Are the named arachidonic acid endpoint and exact measure verified?", "needed": "Aggregation-test methods, specimen/equipment, agonist concentration, measure/unit and assessment procedures for the selected response.", "role": "Required", "role_reason": "Existence of a name and actual measurement are different facts.", "application_exception": "Do not select broad maximum aggregation or threshold as the exact measure for this response.", "criterion": "Retain the endpoint name in the crux; verify maximum aggregation/threshold, agonist concentration, specimen, test method, unit and direction.", "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.", "condition_origin": "These are in-house application conditions for the gap in direct AGE results for arachidonic acid-induced aggregation, developed with knowledge of the retained content. They do not establish blinding, clinical preregistration, official-method certification or independent clinical validation.", "proposed_research": "Directly link methods to result measures; distinguish ADP/other-agonist material." }, { "item_id": "N08", "question_type": "Evidence condition", "question": "Are allocation, blinding and co-use for a direct arachidonic acid comparison verified?", "needed": "Original methods, comparator composition, allocation/concealment, co-use/adherence and assessment blinding for the selected response.", "role": "Required", "role_reason": "An RCT label alone does not establish that a comparison for another response exists.", "application_exception": "Do not turn an unverified selected-response study into an established parallel/crossover design or randomization failure.", "criterion": "Verify actual comparator, allocation/concealment, baseline, co-use/adherence and assessment procedures for the selected-response result.", "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.", "condition_origin": "These are in-house application conditions for the gap in direct AGE results for arachidonic acid-induced aggregation, developed with knowledge of the retained content. They do not establish blinding, clinical preregistration, official-method certification or independent clinical validation.", "proposed_research": "Identify a direct selected-response report before comparing its methods with actual conduct." }, { "item_id": "N09", "question_type": "Evidence condition", "question": "Are the actual direction and effect value for arachidonic acid verified?", "needed": "Selected-response result tables, original arm-level observations, effect direction/unit and contrast definition.", "role": "Required", "role_reason": "Do not invent positive, no-difference or unfavorable results.", "application_exception": "Do not turn an unverified result into an effect of 0, a null effect or an opposing result.", "criterion": "Link original results, between-arm/within-arm contrasts, unit, timing and analysis for this response to an actual report.", "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.", "condition_origin": "These are in-house application conditions for the gap in direct AGE results for arachidonic acid-induced aggregation, developed with knowledge of the retained content. They do not establish blinding, clinical preregistration, official-method certification or independent clinical validation.", "proposed_research": "Extract the selected-response result directly from the original report; attribute actual values, comparison and time." }, { "item_id": "N10", "question_type": "Evidence condition", "question": "Are allocation, analysis and missing-data n for arachidonic acid verified?", "needed": "Arm-level flow, measured/analyzed n and reasons/handling of missing data for each selected-response aggregation test.", "role": "Required", "role_reason": "Totals for other endpoints are not selected-response denominators.", "application_exception": "Do not add 34 and 595 or calculate a new unique participant count.", "criterion": "Verify arm-specific allocated/measured/completed/analyzed n, attrition reasons and missing-data handling for the selected response.", "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.", "condition_origin": "These are in-house application conditions for the gap in direct AGE results for arachidonic acid-induced aggregation, developed with knowledge of the retained content. They do not establish blinding, clinical preregistration, official-method certification or independent clinical validation.", "proposed_research": "Link analysis populations to reports, participants and aggregation tests; do not substitute overall totals across them." }, { "item_id": "N11", "question_type": "Evidence condition", "question": "Are selected-response analysis, variance, CI and important differences verified?", "needed": "Selected-response analysis plans, estimates, variance/CI and support for important-difference criteria.", "role": "Required", "role_reason": "Do not judge precision or sufficiency from broad axes or sample sizes.", "application_exception": "Do not invent CI, P, an effect of 0 or a minimum participant threshold.", "criterion": "Verify models, assignment/adherence effects, SD/SE, CI and important-difference criteria for arachidonic acid estimates.", "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.", "condition_origin": "These are in-house application conditions for the gap in direct AGE results for arachidonic acid-induced aggregation, developed with knowledge of the retained content. They do not establish blinding, clinical preregistration, official-method certification or independent clinical validation.", "proposed_research": "When actual estimates and intervals are obtained, compare them with planned analyses and important-difference criteria." }, { "item_id": "N12", "question_type": "Evidence condition", "question": "Are planned versus actual arachidonic acid measurement or omission verified?", "needed": "Original registration/protocols, complete agonist plans, actual aggregation tests/results and change history.", "role": "Required", "role_reason": "Do not turn a summary gap into established selective reporting across the entire paper.", "application_exception": "Do not treat unobtained registration as nonregistration or a crux name as preregistration.", "criterion": "Verify selected-response plans, registration, dose/concentration/timing, analysis, actual publication reporting and reasons for changes.", "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.", "condition_origin": "These are in-house application conditions for the gap in direct AGE results for arachidonic acid-induced aggregation, developed with knowledge of the retained content. They do not establish blinding, clinical preregistration, official-method certification or independent clinical validation.", "proposed_research": "Compare initial plans with actual specimens/results; distinguish unplanned, unmeasured, summary-omitted and unreported results." }, { "item_id": "N13", "question_type": "Evidence condition", "question": "Are other-agonist signals from the 34-person AGE trial retained unchanged?", "needed": "S01's complete agonist plans/results, dose-specific tables and presence/absence of the selected response.", "role": "Required", "role_reason": "Do not erase existing positive adjacent evidence merely to leave a gap.", "application_exception": "Do not substitute ADP threshold for reduced arachidonic acid maximum aggregation.", "criterion": "Retain S01's partial collagen/epinephrine reductions and weak highest-dose ADP threshold under their original endpoints; do not transfer them to the selected response.", "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.", "condition_origin": "These are in-house application conditions for the gap in direct AGE results for arachidonic acid-induced aggregation, developed with knowledge of the retained content. They do not establish blinding, clinical preregistration, official-method certification or independent clinical validation.", "proposed_research": "Retain other-agonist signals; compare actual planning, measurement and results for the selected response against the original report." }, { "item_id": "N14", "question_type": "Evidence condition", "question": "Is the opposing 1995 result retained without transferring it to the selected response?", "needed": "Complete 1995 product/agonist methods, results and formulation specifications.", "role": "Required", "role_reason": "Prevent both discarding an opposing result and transferring it to the wrong selected response.", "application_exception": "Do not treat nonsignificance as equivalence, AGE ineffectiveness or arachidonic acid ineffectiveness.", "criterion": "Retain the 1995 ADP/PAF/collagen result and unverified preparation identity; distinguish them from direct arachidonic acid refutation.", "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.", "condition_origin": "These are in-house application conditions for the gap in direct AGE results for arachidonic acid-induced aggregation, developed with knowledge of the retained content. They do not establish blinding, clinical preregistration, official-method certification or independent clinical validation.", "proposed_research": "Compare the product and complete endpoint table; verify whether the selected response is direct and the original scope of the opposing result." }, { "item_id": "N15", "question_type": "Evidence condition", "question": "Are the broad 12-RCT review results and inclusion scope for the selected response verified?", "needed": "Review included-trial tables, products/agonists, results/timing, denominators and overlap tables.", "role": "Required", "role_reason": "Review direction and direct selected-response results are different facts.", "application_exception": "Do not turn 6 positive trials into 6 positive selected-response trials or count the review as separate clinical replication.", "criterion": "Retain the review's 12 RCTs, 595 people and 6 positive/rest null results; verify actual included AGE/arachidonic acid trials and results.", "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.", "condition_origin": "These are in-house application conditions for the gap in direct AGE results for arachidonic acid-induced aggregation, developed with knowledge of the retained content. They do not establish blinding, clinical preregistration, official-method certification or independent clinical validation.", "proposed_research": "Separate the review by formulation and agonist; compare positive/no-difference results and directly eligible scope." }, { "item_id": "N16", "question_type": "Evidence condition", "question": "Are the same 34 people, review included trials and selected-response families distinguished?", "needed": "A linkage table for registration/papers, recruitment/period, product, selected-response results and review included trials.", "role": "Required", "role_reason": "Do not count the same participants as independent populations for different endpoints.", "application_exception": "Do not assume that an arachidonic acid selected-response family exists or automatically generate unique counts.", "criterion": "Verify the same 34 people across original doses/endpoints and overlap from review recitation/included trials; leave the selected-response unique-family count unresolved.", "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.", "condition_origin": "These are in-house application conditions for the gap in direct AGE results for arachidonic acid-induced aggregation, developed with knowledge of the retained content. They do not establish blinding, clinical preregistration, official-method certification or independent clinical validation.", "proposed_research": "Create a report-trial-specimen/participant-endpoint linkage table; distinguish multiple reports and included trials." }, { "item_id": "N17", "question_type": "Evidence condition", "question": "Is independent direct AGE arachidonic acid replication verified?", "needed": "Identity, product, population, comparison, results/timing and family tables for unique direct selected-response trials.", "role": "Required", "role_reason": "Do not inherit original R0/I1 as an individual selected-response replication verdict.", "application_exception": "Unverified does not establish 0 studies worldwide or absence of effect.", "criterion": "Verify unique independent results under matching selected-response formulation, population, comparison, measure and timing conditions.", "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.", "condition_origin": "These are in-house application conditions for the gap in direct AGE results for arachidonic acid-induced aggregation, developed with knowledge of the retained content. They do not establish blinding, clinical preregistration, official-method certification or independent clinical validation.", "proposed_research": "After verifying directly eligible conditions, compare independent-family results and differences in conditions." }, { "item_id": "N18", "question_type": "Evidence condition", "question": "Are original funding clues and selected-response product/author independence verified?", "needed": "Funding/COI, product support and author/institution information for original reports and included trials.", "role": "Supplementary; required for independence claims", "role_reason": "Unverified funding establishes neither independent funding nor absence of bias.", "application_exception": "Do not use the generic English funding field as actual verification of selected-response interests.", "criterion": "Retain S01 unverified product-support details, S02 unverified funding and S03 academic/mixed funding; verify selected-response funding/product/author/COI.", "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.", "condition_origin": "These are in-house application conditions for the gap in direct AGE results for arachidonic acid-induced aggregation, developed with knowledge of the retained content. They do not establish blinding, clinical preregistration, official-method certification or independent clinical validation.", "proposed_research": "Identify an eligible selected-response report before separately comparing funding, product and author relationships." }, { "item_id": "N19", "question_type": "Evidence condition", "question": "Are bleeding, event collection, denominators and follow-up for selected-response exposure verified?", "needed": "A product-matched safety population, AE definitions/collection, event/person counts, exposure/follow-up and discontinuation/comparison.", "role": "Supplementary; required for numerical harm claims", "role_reason": "Do not convert unverified harms into no harm.", "application_exception": "Do not turn an unrecorded selected-response result into 0 events or substitute 34/595 as harm denominators.", "criterion": "Distinguish the aggregation-test gap from actual bleeding/severity/discontinuation definitions, comparisons, event/person counts, exposure/follow-up and collection.", "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.", "condition_origin": "These are in-house application conditions for the gap in direct AGE results for arachidonic acid-induced aggregation, developed with knowledge of the retained content. They do not establish blinding, clinical preregistration, official-method certification or independent clinical validation.", "proposed_research": "Link selected-response exposure to actual safety populations/events; distinguish aggregation-test results from risk values." }, { "item_id": "N20", "question_type": "Evidence condition", "question": "Are original bleeding warnings and direct co-use/vulnerable-group data verified?", "needed": "Products, exposure, events, follow-up, alternative explanations and original warning sources by co-use/group.", "role": "Supplementary; required for the stated safety claim", "role_reason": "Retain warnings separately from the efficacy gap.", "application_exception": "Retaining an original warning creates no new harm-causality verdict, safety grade or dosing prescription.", "criterion": "Retain original anticoagulant/antiplatelet, bleeding-disorder and surgical warnings; verify direct selected-response exposure, events/alternatives and long-term/rare-harm information.", "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.", "condition_origin": "These are in-house application conditions for the gap in direct AGE results for arachidonic acid-induced aggregation, developed with knowledge of the retained content. They do not establish blinding, clinical preregistration, official-method certification or independent clinical validation.", "proposed_research": "Compare original warning support and actual group-specific safety data separately; do not certify personal safety." }, { "item_id": "N21", "question_type": "Evidence condition", "question": "Does the named response also answer thrombosis-prevention or treatment-replacement questions?", "needed": "Definitions, comparators, denominators, follow-up and clinical results for a separate event question.", "role": "Supplementary; required only for clinical extensions", "role_reason": "An experimental response name alone does not establish clinical prevention.", "application_exception": "Not applicable does not mean no clinical events, no harm or an effect of 0.", "criterion": "Distinguish the selected-response aggregation-test gap from separate questions of clinical thrombosis/bleeding, thrombolysis and aspirin replacement.", "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.", "condition_origin": "These are in-house application conditions for the gap in direct AGE results for arachidonic acid-induced aggregation, developed with knowledge of the retained content. They do not establish blinding, clinical preregistration, official-method certification or independent clinical validation.", "proposed_research": "Frame clinical-event questions under separate conditions; examine designs/follow-up different from aggregation testing." }, { "item_id": "N22", "question_type": "Evidence condition", "question": "Are optimal dose, long-term effects and subgroups needed for this gap question?", "needed": "If an extension is requested, direct selected-response dose comparisons, discontinuation/long-term and prespecified subgroup data.", "role": "Supplementary; required only for extension claims", "role_reason": "Do not repurpose another dose trial as selected-response optimization.", "application_exception": "Do not erase other favorable results because a direct selected-response result is unavailable.", "criterion": "Distinguish direct selected-response result identity from separate dose, discontinuation/long-term and subgroup-effect questions.", "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.", "condition_origin": "These are in-house application conditions for the gap in direct AGE results for arachidonic acid-induced aggregation, developed with knowledge of the retained content. They do not establish blinding, clinical preregistration, official-method certification or independent clinical validation.", "proposed_research": "After verifying direct selected-response conditions, separately review prespecified analyses and effect modification for each extension." }, { "item_id": "N23", "question_type": "Evidence condition", "question": "Are local summaries of the reports distinguished from unread external material?", "needed": "Actual material-specific access/acquisition/reading records, versions/locations and physical material.", "role": "Required", "role_reason": "A link or summary does not establish acquisition of original selected-response material.", "application_exception": "Do not inherit a report's access history onto a DOI gateway or treat unattempted access as failed access.", "criterion": "Distinguish 3 evidence entries/3 citations and actual Korean/English local reading from unattempted, unacquired and unread external PubMed/DOI/full texts.", "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.", "condition_origin": "These are in-house application conditions for the gap in direct AGE results for arachidonic acid-induced aggregation, developed with knowledge of the retained content. They do not establish blinding, clinical preregistration, official-method certification or independent clinical validation.", "proposed_research": "In authorized later reading, record material, level and version separately; compare summaries against original results." }, { "item_id": "N24", "question_type": "Evidence condition", "question": "Are original reference dates and corrections distinguished from individual access dates?", "needed": "Historical material-specific access/version records and complete versions before/after corrections.", "role": "Required", "role_reason": "A global review date is not an access date for each external material.", "application_exception": "Do not turn historical research descriptions into current reading of arachidonic acid full texts.", "criterion": "Retain the original review date 2026-09-08 and correction 2026-09-14; distinguish the actual current date from unrecorded individual access dates.", "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.", "condition_origin": "These are in-house application conditions for the gap in direct AGE results for arachidonic acid-induced aggregation, developed with knowledge of the retained content. They do not establish blinding, clinical preregistration, official-method certification or independent clinical validation.", "proposed_research": "Separate reference-date, correction and actual-reading events; compare dates and material levels." }, { "item_id": "N25", "question_type": "Evidence condition", "question": "Is the scope of a current complete literature check for the arachidonic acid gap available?", "needed": "Contemporaneous queries/dates, inclusion/exclusion, agonist/formulation candidates and unpublished/correction/retraction logs.", "role": "Required", "role_reason": "Reading the complete current source differs from an exhaustive current clinical-literature check.", "application_exception": "Do not turn 0 new searches into 0 selected-response studies or established nonreporting across the entire paper.", "criterion": "Verify actual queries, dates, inclusion/exclusion, unpublished/correction logs and the scope of the complete current evidence check for AGE arachidonic acid. Separately state the current summary gap and that no new search was performed.", "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.", "condition_origin": "These are in-house application conditions for the gap in direct AGE results for arachidonic acid-induced aggregation, developed with knowledge of the retained content. They do not establish blinding, clinical preregistration, official-method certification or independent clinical validation.", "proposed_research": "In a separately authorized update, reproduce search scope using the named response and product conditions; compare actual omissions." }, { "item_id": "N26", "question_type": "Evidence condition", "question": "Are the C46 parent history and individual arachidonic acid status distinguished?", "needed": "The complete original summary, identity, boundaries/verdict/corrections and derived-grade policy.", "role": "Required", "role_reason": "The broad parent grade does not verify a direct selected-response effect.", "application_exception": "Do not turn an unrecorded observation into a numeric 0 or null effect.", "criterion": "Retain original grade/score/axes/Warning, all evidence values, empty arrays and corrections; explicitly state that a separate selected-response grade is unrecorded.", "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.", "condition_origin": "These are in-house application conditions for the gap in direct AGE results for arachidonic acid-induced aggregation, developed with knowledge of the retained content. They do not establish blinding, clinical preregistration, official-method certification or independent clinical validation.", "proposed_research": "Compare complete preserved original/case values and change events to check that no new selected-response verdict has been created." } ] }